Market Place
Sourcing Support
All News #Library
Biotech
Apellis to Deliver Eight Oral Talks at Macula Society Meeting
19 Feb 2026 //
GLOBENEWSWIRE
Ocugen Update Charts Course For Rivalry With Apellis, Astellas
15 Jan 2026 //
FIERCE BIOTECH
Apellis: Syfovre Delays Geographic Atrophy by ~1.5 Years
12 Nov 2025 //
GLOBENEWSWIRE
Empaveli 1-Year Data Confirms Sustained Efficacy in C3G, IC-MPGN
20 Oct 2025 //
GLOBENEWSWIRE
Apellis` Syfovre faces tough road ahead in GA market
14 May 2025 //
FIERCE PHARMA
Apellis Pharmaceuticals Reports Q1 2025 Financial Results
07 May 2025 //
GLOBENEWSWIRE
Apellis Announces Craig Wheeler to Join the Board of Directors
21 Apr 2025 //
GLOBENEWSWIRE
Apellis, Sobi’s Aspaveli Gets EMA Validate For C3G & IC-MPGN Expansion
20 Feb 2025 //
GLOBENEWSWIRE
Apellis Presents Phase 3 VALIANT Study At ASN Kidney Week
16 Oct 2024 //
GLOBENEWSWIRE
Apellis Seeks Re-Examination Following Negative CHMP Opinion For Pegcetacoplan
28 Jun 2024 //
GLOBENEWSWIRE
Pegcetacoplan 1-Year C3G Ic-Mpgn: Positive Post-Transplant Data At Era
24 May 2024 //
GLOBENEWSWIRE
Apellis: Pegcetacoplan MAA Review Reset by EMA
26 Apr 2024 //
GLOBENEWSWIRE
Apellis Pharma Gets Negative CHMP Opinion for Intravitreal Pegcetacoplan
27 Jan 2024 //
PRESS RELEASE
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA
14 Dec 2023 //
GLOBENEWSWIRE
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan
17 Oct 2023 //
GLOBENEWSWIRE
Apellis scraps pegcetacoplan development in ALS after trial flop
26 May 2023 //
FIERCE PHARMA
Apellis stops dosing of pegcetacoplan in ALS trial after data review
10 May 2023 //
ALSNEWSTODAY
Apellis Announces Validation of 4Marketing Applications for Pegcetacoplanrophy
21 Apr 2023 //
GLOBENEWSWIRE
BlackRock Increases Position in Apellis Pharmaceuticals (APLS)
01 Feb 2023 //
NASDAQ
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.